Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors

Alba Chimirri; De Clercq Erik; Giovanni Maga; Patrizia Logoteta; Stefania Ferro; Laura De Luca; Nunzio Iraci; Christophe Pannecouque; Anna‐Maria Monforte

doi:10.1016/j.antiviral.2009.02.133

Article2003

Anti-HIV agents: design and discovery of new potent RT inhibitors

Maria Letizia Barreca, Alba Chimirri, De Clercq Erik, Laura De Luca, Anna‐Maria Monforte, Pietro Monforte, Angela Rao, Maria Zappalà

Article2003

anti‐HIV Agents: Design and Discovery of New Potent RT Inhibitors.

Maria Letizia Barreca, Alba Chimirri, De Clercq Erik, Laura De Luca, Anna‐Maria Monforte, Pietro Monforte, Angela Rao, Maria Zappalà

Article2010

Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication

Renato T. Skerlj, Gary Bridger, Ernest J. McEachern, Curtis Harwig, Christopher R. Smith, Trevor Wilson, D. R. VEALE, Helen S. Yee, Jason Crawford, Krystyna A. Skupinska, Rossana Wauthy, Wen Yang, Yongbao Zhu, David Bogucki, Maria Di Fluri, Jonathon Langille, Dana Huskens, De Clercq Erik, Dominique Schols

Article2009

Design, Synthesis, and SAR of Naphthyl‐Substituted Diarylpyrimidines as Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase

Yonghong Liang, Xiaoqing Feng, Zhao‐Sen Zeng, Fen‐Er Chen, Jan Balzarini, Christophe Pannecouque, De Clercq Erik

Article1992

Differential kinetics and susceptibilities of mutagenized HIV-1 reverse transcriptases (RT) to HIV-1-specific RT inhibitors

Zeger Debyser, K De Vreese, Rudi Pauwels, Jozef Anné, De Clercq Erik

Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors

Discussion(0)

Related publications

Anti-HIV agents: design and discovery of new potent RT inhibitors

anti‐HIV Agents: Design and Discovery of New Potent RT Inhibitors.

Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication

Design, Synthesis, and SAR of Naphthyl‐Substituted Diarylpyrimidines as Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase

Differential kinetics and susceptibilities of mutagenized HIV-1 reverse transcriptases (RT) to HIV-1-specific RT inhibitors